ACB vs. CRON, USNA, CGC, MNMD, BTMD, CDXC, MDWD, FTLF, NAII, and BGXX
Should you be buying Aurora Cannabis stock or one of its competitors? The main competitors of Aurora Cannabis include Cronos Group (CRON), USANA Health Sciences (USNA), Canopy Growth (CGC), Mind Medicine (MindMed) (MNMD), biote (BTMD), ChromaDex (CDXC), MediWound (MDWD), FitLife Brands (FTLF), Natural Alternatives International (NAII), and Bright Green (BGXX). These companies are all part of the "medicinals & botanicals" industry.
Cronos Group (NASDAQ:CRON) and Aurora Cannabis (NASDAQ:ACB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, community ranking, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership.
8.7% of Cronos Group shares are held by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are held by institutional investors. 6.9% of Cronos Group shares are held by insiders. Comparatively, 0.0% of Aurora Cannabis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Cronos Group had 5 more articles in the media than Aurora Cannabis. MarketBeat recorded 8 mentions for Cronos Group and 3 mentions for Aurora Cannabis. Cronos Group's average media sentiment score of 0.47 beat Aurora Cannabis' score of 0.23 indicating that Aurora Cannabis is being referred to more favorably in the news media.
Cronos Group received 83 more outperform votes than Aurora Cannabis when rated by MarketBeat users. Likewise, 61.13% of users gave Cronos Group an outperform vote while only 59.44% of users gave Aurora Cannabis an outperform vote.
Cronos Group has higher earnings, but lower revenue than Aurora Cannabis. Cronos Group is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.
Cronos Group presently has a consensus target price of $3.00, indicating a potential upside of 15.83%. Given Aurora Cannabis' higher possible upside, equities research analysts clearly believe Cronos Group is more favorable than Aurora Cannabis.
Aurora Cannabis has a net margin of -48.82% compared to Aurora Cannabis' net margin of -61.31%. Aurora Cannabis' return on equity of -3.06% beat Cronos Group's return on equity.
Cronos Group has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. Comparatively, Aurora Cannabis has a beta of 1.96, meaning that its share price is 96% more volatile than the S&P 500.
Summary
Cronos Group beats Aurora Cannabis on 10 of the 18 factors compared between the two stocks.
Get Aurora Cannabis News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aurora Cannabis Competitors List
Related Companies and Tools
